SK Biopharm’s new drug tops 500 bln won in US sales
By Kim, Jin-Gu | translator Kim, Jung-Ju
24.01.30 05:50:42
가나다라
0
SK Biopharmaceuticals reached 270 billion won in sales in the U.S. market last year
After eight quarters since Q4 of 2021, SK Biopharmaceuticals shifted to a net profit from repeated operating losses
SK Biopharmaceuticals has completed establishing its direct sales strategy and inventory adjustment in the United States …“We anticipate a high gross profit margin of 90% or more”
▲SK Biopharmaceuticals.
SK Biopharmaceuticals’ Cenobamate, a new epilepsy drug, has generated cumulative sales of 500 billion won in the United States since its launch four years ago.
Previously, SK Biopharmaceuticals struggled with operating losses almost every quarter, except for occasional profits from technology exports. However, the company has now turned to achieve profits, primarily attributed to the success of Cenobamate. With its U.S. direct sales system in place, SK Biopharmaceuticals anticipates a high gross profit margin increase of mid-90%.
SK Biopharm’s operating profit reached 15.2 billion won in Q4 last year, swinging to profitability after eight quarters of loss
A
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)